Gil Beyen – Chief Executive Officer

Gil Beyen is Chief Executive Officer of ERYTECH Pharma since May 2013 and President of ERYTECH Pharma Inc. since 2016. He served as ERYTECH’s Chairman of the Board from August 2012 until June 2019. Between 2000 and 2013, Mr. Beyen was Chief Executive Officer and Director of TiGenix (Euronext: TIG), a company he co-founded. He previously served as the head of the Life Sciences division of Arthur D. Little, an international management consulting firm, in Brussels. Mr. Beyen holds a MSc in Bioengineering from the University of Leuven (Belgium) and an M.B.A. from the University of Chicago.


Eric Soyer – Chief Financial Officer & Chief Operating Officer

Eric joined Erytech in 2015. Eric Soyer has a more than 20 year experience in Management positions in financial and operational fields in public or private companies including eight years as Chief Financial Officer of EDAP TMS S.A., and Managing Director of the French affiliate Chief Financial Officer for a company operating nursing homes and post-care clinics, Financial and legal director for an insurance services company. He started his career as a financial controller and cost accountant for Michelin Group. Eric Soyer graduated from the ESC Clermont School of Management (France) and holds an M.B.A. from the University of Kansas and an Executive M.B.A. from the HEC Paris School of Management (France).


Iman El-Hariry, MD, PhD – Chief Medical Officer

Iman El-Hariry, M.D., Ph.D. has served as our Chief Medical Officer and employee of our wholly-owned U.S. subsidiary, ERYTECH Pharma, Inc., since June 2015. Prior to her appointment as Chief Medical Officer, she served as President of Azure Oncology Consulting from July 2014 to June 2015 and also assisted us in a consulting role from November 2014 to June 2015. Dr. El-Hariry served as Vice President of Clinical Research at Synta Pharmaceuticals from November 2010 to July 2014 and as Global Head of Oncology at Astellas Pharma, Inc. from June 2009 to July 2010. From 2001 to 2009, she served as Director of Clinical Development, Oncology at Glaxo Smith Kline. Dr. El-Hariry is a licensed oncologist with an M.D. from Alexandria Medical School (Egypt) and a Ph.D. in Cancer Research from Imperial College of Science and Medicine (United Kingdom).


Jérôme Bailly, Pharm.D. – Chief Quality Officer, Deputy General Manager and Qualified Person

Jérôme Bailly, Pharm.D. has served as our Qualified Person since December 2011, and has served as our Director of Pharmaceutical Operations since 2007. Prior to 2007, he was the Director of QA/Production at Skyepharma and Laboratoire Aguettant. Dr. Bailly holds a Pharm.D. and a degree in Chemica Engineering, specializing in Biopharmaceutical Engineering and Cellular Production from École Polytechnique de Montréal (Canada).


Karine Charton, PhD – Director Innovation & Valorization

Karine joined Erytech Pharma in September 2017, leading early-stage business development. She was appointed Director Innovation and Valorization in 2022. In this role, she is leading Erytech’s preclinical research and development team and external innovation efforts. Prior to joining Erytech Pharma, Karine was a researcher in charge of R&D programs in the non-profit company Généthon, dedicated to developing gene therapies for rare diseases, where she developed deep experience in innovative product development in the gene therapy space. She then moved to the Scientific Direction of AFM-Téléthon to support detection, valorization and follow-up of projects to be funded in the field of rare diseases.


Anne-Cécile Fumey – Human Resources Director

Anne-Cécile Fumey was appointed Human Resources Director at Erytech Pharma in February 2016. Prior to joining the company, Mrs. Fumey served within several high-growth blue-chip companies. She was International HR Director with Clasquin Group and Senior HR Manager at National Bank of Canada in Montréal. Anne-Cécile Fumey started her career with BD where she was responsible for Human Resources management at the European headquarters, then within the Pharmaceutical Systems business unit, before being appointed Compensation and Benefits Manager France.

Mrs. Fumey graduated from the Grenoble Institute of Political Studies (IEP) and has a postgraduate degree (DESS) in Human Resources Management from the Grenoble Graduate School of Management (IAE).


Brian Schwab – Chief Legal Officer & General Counsel

Brian Schwab joined ERYTECH Pharma in January 2020 as VP, Legal Affairs & General Counsel and has over 25 years of French and US in-house and law firm experience. Prior to his appointment, he served as General Counsel to two Global Business Units at Solvay in Lyon and as Chief Licensing Officer and General Counsel at Scynexis, in North Carolina. He previously served as Deputy General Counsel at Aventis CropScience and as Senior Legal Counsel at Rhone-Poulenc. Mr. Schwab also worked as an attorney for Freshfields Bruckhaus Deringer in Paris and for Cooley LLP in Palo Alto, California. Mr. Schwab received a B.A. from Cornell University, a law degree from the University of California – Los Angeles and a LLM degree from the University of Maastricht in the Netherlands.

Menu